Publications

Peer-Reviewed Articles

2022

  1. Johnson B, Zhuang L, Rath EM, Yuen ML, Cheng NC, Shi H, Kao S, Reid G, Cheng YY. Exploring microRNA and exosome involvement in malignant pleural mesothelioma drug response. Cancers (Basel). 2022 Sep 30;14(19):4784. doi: 10.3390/cancers14194784.  PMID: 36230710.
  2. Jeffers D, Liao YC, Takahashi K, Lin RT. Asbestos awareness among the residents of St. Kitts and Nevis: a cross-sectional study. Global Health. 2022 Sep 24;18(1):83.
    doi: 10.1186/s12992-022-00874-w.  PMID: 36153532.
  3. Shi H, Rath EM, Lin RCY, Sarun KH, Clarke CJ, McCaughan BC, Ke H, Linton A, Lee K, Klebe S, Maitz J, Song K, Wang Y, Kao S, Cheng YY. 3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies. Front Oncol. 2022 Aug 26;12:973576. doi: 10.3389/fonc.2022.973576.  eCollection 2022.  PMID: 36091141.
  4. Global Burden of Disease 2019 Cancer Risk Factors Collaborators (Soeberg M, Leigh J, included). The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019. 2022 Aug 20;400(10352):563-91. doi: 10.1016/S0140-6736(22)01438-6. PMID: 35988567.
  5. Khoa ND, Phuong NL, Takahashi K, Ito K. Transport and deposition of inhaled man-made vitreous and asbestos fibers in realistic human respiratory tract models: An in silico study. Jpn Archit Rev. 2022 Aug;00:1-17. doi: 10.1002/2475-8876.12277.  Article in Press.  PMID:
  6. Lee JT, Mittal DL, Warby A, Kao S, Dhillon HM, Vardy JL. Dying of mesothelioma: A qualitative exploration of caregiver experiences. Eur J Cancer Care (Engl). 2022 June 20:e13627.  doi: 10.1111/ecc.13627.  Online ahead of print.  PMID: 35723508.
  7. Ke H, Kao S, Lee K, Takahashi K, Goh HP, Linton A. The minimum standard of care for managing malignant pleural mesothelioma in developing nations within the Asia-Pacific Region. Asia Pac J Clin Oncol. 2022 Jun;18(3):177-90.  doi: 10.1111/ajco.13611.  Epub 2021 Jun 23.  PMID: 34161674.
  8. Rath EM, Yuen ML, Odgerel CO, Lin RT, Soeberg M, Nowak AK, Takahashi K. The ecological association between asbestos consumption and asbestos-related diseases 15 years later. Environ Health Perspect. 2022 May;130(5):57703. doi: 10.1289/EHP11148.  Epub 2022 May 27. PMID: 35622389.
  9. McLean AEB, Kao SC, Barnes DJ, Wong KKH, Scolyer RA, Cooper WA, Kohonen-Corish MRJ. Corrigendum to "The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment" [Lung Cancer 165C (2022) 124-132]. Lung Cancer. 2022 Apr;166:252. doi: 10.1016/j.lungcan.2022.02.011.  Epub 2022 Mar 9.  PMID: 35279297.
  10. Whittle K, Kao S, Clarke S, Grau GER, Hosseini-Beheshti E. Exploring the role of extracellular vesicles and their protein cargo in lung cancer metastasis: A review. Crit Rev Oncol Hematol. 2022 Mar;171:103603. doi: 10.1016/j.critrevonc.2022.103603.  Epub 2022 Jan 20.  PMID: 35066154.
  11. Kottek M, Yuen ML. Public health risks from asbestos cement roofing. Am J Ind Med. 2022 Mar;65(3):157-61.  doi: 10.1002/ajim.23321.  Epub 2021 Dec 28.  PMID: 34962302.
  12. Davis A, Ke H, Kao S, Pavlakis N. An update on emerging therapeutic options for malignant pleural mesothelioma. Lung Cancer (Auckl). 2022 Mar 2;13:1-12.
    doi: 10.2147/LCTT.S288535.  eCollection 2022.  PMID: 35264891.
  13. Global Burden of Disease 2019 Cancer Collaboration (Takahashi K, Soeberg M, Leigh J, included). Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022 Mar 1;8(3):420-44.
    doi: 10.1001/jamaoncol.2021.6987.  PMID: 34967848.
  14. Hyland RA, Chrzanowska A, Hannaford-Turner K, Davis A, Ke H, Bradbury L, Nagrial A, McCaughan B, Hui R, van Zandwijk N, Takahashi K, Kao SC. Asbestos-related lung cancer: Clinical characteristics and survival outcomes in an Australian cohort seeking workers compensation. Asia Pac J Clin Oncol. 2022 Jan 31. doi: 10.1111/ajco.13664.
    PMID: 35100476. Online ahead of print.
  15. McLean AEB, Kao SC, Barnes DJ, Wong KKH, Scolyer RA, Cooper WA, Kohonen-Corish MRJ. The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment. Lung Cancer. 2022 Jan 20;165:124-32.
    doi: 10.1016/j.lungcan.2022.01.011.  Online ahead of print.  PMID: 35123155.
  16. Global Burden of Disease 2019 Adolescent Young Adult Cancer Collaborators (Takahashi K, included). The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Oncol. 2022 Jan;23(1):27-52. doi: 10.1016/S1470-2045(21)00581-7.  Epub 2021 Dec 3.
    PMID: 34871551.
  17. Chimed-Ochir O, Delgermaa V, Takahashi K, Purev O, Sarankhuu A, Fujino Y, Bayarmagnai N, Dugee O, Erkhembayar R, Lkhagvaa B, Ochir C, Sosorburam T, Naghavi M. Mongolia health situation: based on the Global Burden of Disease Study 2019. BMC Public Health. 2022 Jan 4;22(1):5.  doi: 10.1186/s12889-021-12070-3.  PMID: 34983445.

2021

  1. Klebe S, Hocking AJ, Soeberg M, Leigh J. The significance of short latency in mesothelioma for attribution of causation: report of a case with predisposing germline mutations and review of the literature. Int J Environ Res Public Health. 2021 Dec 17;18(24):13310. doi: 10.3390/ijerph182413310.  PMID: 34948918.
  2. Johnson BW, Takahashi K, Cheng YY. Preclinical models and resources to facilitate basic science research on malignant mesothelioma - a review. Front Oncol. 2021 Nov 11;11:748444. https://doi.org/10.3389/fonc.2021.748444. PMID: 34900693.
  3. Davis AP, Kao SC, Clarke SJ, Boyer M, Pavlakis N. Emerging biological therapies for the treatment of malignant pleural mesothelioma. Expert Opin Emerg Drugs. 2021 Jun;26(2):179-192. doi: 10.1080/14728214.2021.1924670. Epub 2021 May 17.
    PMID: 33945357.
  4. Ke H, Gill AJ, McKenzie C, Kench JG, Chan RCF, Pavlakis N, Fulham M, Koh C, Kao S. Malignant peritoneal mesothelioma with EWSR1-ATF1 fusion: a case report. JTO Clin Res Rep. 2021 Oct 11;2(11):100236. doi: 10.1016/j.jtocrr.2021.100236. PMID: 34766064; PMCID: PMC8569551.
  5. Davis AP, Cooper WA, Boyer M, Lee JH, Pavlakis N, Kao SC. Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations. Immunotherapy. 2021 Aug;13(11):941-952. doi: 10.2217/imt-2021-0090. Epub 2021 Jun 11. PMID: 34114474.
  6. Johnson B, Lee K, Cheng YY. Pre-clinical research advancements relating to improving the diagnosis and treatment of malignant pleural mesothelioma: a review. 2021 Sep 26;1(2):49-82. https://doi.org/10.3390/onco1020006. PMID:
  7. Yuen ML, Zhuang L, Rath EM, Yu T, Johnson B, Sarun KH, Wang Y, Kao S, Linton A, Clarke CJ, McCaughan BC, Takahashi K, Lee K, Cheng YY. The role of E-Cadherin and microRNA on FAK inhibitor response in malignant pleural mesothelioma (MPM). Int J Mol Sci. 2021 Sep 23;22(19):10225. doi: 10.3390/ijms221910225. PMID: 34638565
  8. GBD 2019 Respiratory Tract Cancers Collaborators (Takahashi K included). Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Respir Med. 2021 Sep;9(9):1030-1049. doi: 10.1016/S2213-2600(21)00164-8. Epub 2021 Aug 16. PMID: 34411511
  9. Takahashi K. Asbestos Diseases Research Institute – A new WHO Collaborating Centre. Editorial. Industrial Health. 2021 Aug 17;59(3):143-145. doi: 10.2486/indhealth.1-3. Epub 2021 Jul 8. PMID: 34234080
  10. Arachi D, Furuya S, David A, Mangwiro A, Chimed-Ochir O, Lee K, Tighe P, Takala J, Driscoll T, Takahashi K. Development of the “National Asbestos Profile” to eliminate asbestos-related diseases in 195 countries. Int J Environ Res Public Health. 2021 Feb 12;18(4):1804. doi: 10.3390/ijerph18041804.  PMID: 33673264
  11. Cheng YY,  Yuen ML, Jin H. Editorial: Epigenetic Modifications in Mesothelioma. Front Oncol. 2021 Feb 3;11:650136.  doi: 10.3389/fonc.2021.650136.  PMID: 33614517

2020

  1. Cheng YY, Yuen ML, Rath EM, Johnson B, Zhuang L, Yu T-K, Aleksova V, Linton A, Kao S, Clarke CJ, McCaughan BC, Takahashi K, Lee K. CDKN2A and MTAP are useful biomarkers detectable by droplet digital PCR in malignant pleural mesothelioma: A potential alternative method in diagnosis compared to fluorescence in situ hybridisation. Front Oncol. 2020 Nov 13;10:579327. doi: 10.3389/fonc.2020.579327. eCollection 2020.  PMID: 33304846
  2. GBD 2019 Diseases and Injuries Collaborators (Takahashi K, included). Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. 2020 Oct 17;396(10258):1204-22. doi: 10.1016/S0140-6736(20)30925-9.  PMID: 33069326
  3. GBD 2019 Risk Factors Collaborators (Takahashi K, included). Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. 2020 Oct 17;396(10258):1223-49. doi: 10.1016/S0140-6736(20)30752-2.  PMID: 33069327
  4. GBD 2019 Viewpoint Collaborators (Takahashi K, included). Five insights from the Global Burden of Disease Study 2019. 2020 Oct 17;396(10258):1135-59. doi: 10.1016/S0140-6736(20)31404-5.  PMID: 33069324
  5. Chimed-Ochir O, Arachi D, Driscoll T, Lin RT, Takala J, Takahashi K. Burden of mesothelioma deaths by national income category: current status and future implications. Int J Environ Res Public Health. 2020 Sep 21;17(18):E6900.  doi: 10.3390/ijerph17186900. PMID: 32967259
  6. Rozitis E, Johnson B, Cheng YY, Lee K. The use of immunohistochemistry, fluorescence in situ hybridization, and emerging epigenetic markers in the diagnosis of malignant pleural mesothelioma (MPM): A Review. Front Oncol. 2020 Sep 9;10:Article 1742. doi: doi.org/10.3389/fonc.2020.01742.  PMID: 33014860
  7. Johnson TG, Schelch K, Lai K, Marzec KA, Kennerson M, Grusch M, Reid G, Burgess A. YB-1 Knockdown Inhibits the Proliferation of Mesothelioma Cells through Multiple Mechanisms. Cancers (Basel). 2020 Aug 14;12(8):2285. doi: 10.3390/cancers12082285. PMID: 32823952; PMCID: PMC7464182.
  8. Lau B, Boyer M, Lee JH, Kao S. Clinical trials eligibility of patients with malignant pleural mesothelioma: use of novel therapies and outcomes. Clin Lung Cancer. 2020 Jul;21(4):378-83 e1. doi: 10.1016/j.cllc.2020.01.007.  Epub 2020 Mar 7.  PMID: 32249197
  9. Ahmadzada T, Kao S, Reid G, Clarke S, Grau GE, Hosseini-Beheshti E. Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review. Crit Rev Oncol Hematol. 2020 Jun; 150:102949.doi: 10.1016/j.critrevonc.2020.102949. Epub 2020 Apr 9. PMID: 32330840
  10. Chaw L, Chien LC, Wong J, Takahashi K, Koh D, Lin RT Global trends and gaps in research related to latent tuberculosis infection. BMC Public Health. 2020 Mar 18;20(1):352. doi: 10.1186/s12889-020-8419-0. PMID: 32183753
  11. Yuen ML, Rath EM, Sarun KH, McCaughan BC, Lee K, Cheng YY. The relationship of molecular biomarker detection and DNA isolation. Biomedical Journal of Scientific & Technical Research. 2020 March 5;26(2):19866-19869. doi: 10.26717/BJSTR.2020.26.004335. Accepted 4 March 2020.
  12. GBD 2016 Occupational Chronic Respiratory Risk Factors Collaborators (Takahashi K, included). Global and regional burden of chronic respiratory disease in 2016 arising from non-infectious airborne occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016. Occup Environ Med. 2020 Mar;77(3):142-50. doi: 10.1136/oemed-2019-106013.  PMID: 32054818
  13. GBD 2016 Occupational Carcinogens Collaborators (Takahashi K, included). Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016. Occup Environ Med. 2020 Mar;77(3):151-9. doi: 10.1136/oemed-2019-106012.  PMID: 32054819
  14. GBD 2016 Occupational Risk Factors Collaborators (Takahashi K, included). Global and regional burden of disease and injury in 2016 arising from occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016. Occup Environ Med. 2020 Mar;77(3):133-41. doi: 10.1136/oemed-2019-106008. PMID: 32054817
  15. Reid G, Johnson TG, van Zandwijk N. Manipulating microRNAs for the treatment of malignant pleural mesothelioma: past, present and future. Front Oncol. 2020 Feb 7;10:105. doi: 10.3389/fonc.2020.00105.  PMID: 32117755
  16. Cheng YY, Rath EM, Linton A, Yuen ML, Takahashi K, Lee K. The current understanding of asbestos-induced epigenetic changes associated with lung cancer. Lung Cancer (Auckl). 2020 Jan 8;11:1-11. doi.org/10.2147/LCTT.S186843  PMID: 32021524
  17. Ahmadzada T, Cooper WA, Holmes M, Mahar A, Westman H, Gill AJ, Nordman I, Yip PY, Pal A, Zielinski R, Pavlakis N, Nagrial A, Daneshvar D, Brungs D, Karikios D, Aleksova V, Burn J, Asher R, Grau GE, Hosseini-Beheshti E, Reid G, Clarke S, Kao S. Retrospective evaluation of the use of pembrolizumab in malignant mesothelioma in a real-world Australian population. JTO Clin Res Rep. 2020 Jul 16;1(4):100075.
    doi: 10.1016/j.jtocrr.2020.100075.  eCollection 2020 Nov.  PMID: 34589956

2019

  1. Williams M, Cheng YY, Kirschner MB, Sarun KH, Schelch K, Winata P, McCaughan B, Kao S, Van Zandwijk N, Reid G. Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma. Oncotarget. 2019 Jun 25;10(41):4125-38. doi: 10.18632/oncotarget.27010.   PMID: 31289611
  2. Global Burden of Disease Cancer Collaboration, (Takahashi K, included). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2019 Sep 27. doi: 10.1001/jamaoncol.2019.2996. [Epub ahead of print].  PMID: 31560378
  3. Johnson TG, Schelch K, Mehta S, Burgess A, Reid G. Why be one protein when you can affect many? The multiple roles of YB-1 in lung cancer and mesothelioma. Front Cell Dev Biol. 2019 Oct 1;7:221. https://doi: 10.3389/fcell.2019.00221. eCollection 2019.   PMID: 31632972
  4. Fan X, McLaughlin C, Robinson C, Ravasini J, Schelch K, Johnson T, van Zandwijk N, Reid G, George AM. Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma. FASEB BioAdvances. 2019;1(9):550-60. https://doi.org/10.1096/fba.2019-00040.   PMID:
  5. Lin R-T, Chien L-C, Jimba M, Furuya S, Takahashi K. Implementation of national policies for a total asbestos ban: A global comparison. Lancet Planet Health 2019 Aug: 3 (8), e341-e348.  DOI: 1016/S2542-5196(19)30109-3 PMID: 31439315
  6. Aekphachaisawat N, Sawanyawisuth K, Khamsai S, Chattakul P, Takahashi K, Chotmongkol V, Tiamkao S, Limpawattana P, Senthong V, Chindaprasirt J, Theeranut A, Ngamjarus C. An ecological study of eosinophilic meningitis caused by the nematode, Angiostrongylus cantonensis (Chen, 1935) (Nematoda: Metastrongylidae). Parasitol Int. 2019 Oct;72:101944. doi: 10.1016/j.parint.2019.101944. Epub 2019 Jun 18.
  7. Warby A, Dhillon HM, Kao S, Vardy JL. Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma. Support Care Cancer. 2019 Sep;27(9):3509-19. doi: 10.1007/s00520-019-4648-0. PMID: 30684047
  8. Linton A, Blinman P, Kao S, van Zandwijk N. Patterns of care and survival of older patients with malignant pleural mesothelioma. J Geriatr Oncol. 2019 Jul;10(4):573-6. doi: 10.1016/j.jgo.2019.02.013.  PMID: 30917938
  9. Warby A, Dhillon HM, Kao S, Vardy JL. A survey of patient and caregiver experience with malignant pleural mesothelioma. Support Care Cancer. 2019;27(12):4675-86. doi: 10.1007/s00520-019-04760-x.  Epub 2019 Apr 3.  PMID: 30944991
  10. McCabe MJ, Pinese M, Chan CL, Sheriff N, Thompson TJ, Grady J, Wong M, Gauthier MEA, Puttick C, Gayevskiy V, Hajdu E, Wong SQ, Barrett W, Earls P, Lukeis R, Cheng YY, Lin RCY, Thomas DM, Watkins DN, Dinger ME, McCormack AI, and Cowley MJ. Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases. Cold Spring Harb Mol Case Stud. 2019 April 1;5(2). doi: 10.1101/mcs.a003764.  PMID: 30936196
  11. Ma Z, Williams M, Cheng YY, Leung WK. Roles of methylated DNA biomarkers in patients with colorectal cancer. Dis Markers. 2019 Mar 3;2019:2673543. doi: 10.1155/2019/2673543.  PMID: 30944663
  12. Cheng YY, Jin H. Epigenetic modification in mesothelioma. Frontiers Research Topics. Frontiers. https://www.frontiersin.org/research-topics/9382/epigenetic-modification-in-mesothelioma

2018

  1. Talaulikar D, Biscoe A, Lim JH, Gibson J, Arthur C, Mackinlay N, Saxena K, Cheng YY, Chen VM. Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenström Macroglobulinaemia reveals different patterns of clonal evolution.  British Journal of Heametology; In press
  2. Rath EM, Cheng YY, Pinese M, Sarun KH, Hudson AL, Weir C, Wang YD, Håkansson AP, Howell VM, Liu GJ, Reid G, Knott RB, Duff AP, Church WB. BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state, PlosOne: 2018 Aug 29: 13 (8):e doi: 10.1371/journal.pone.0203003. eCollection 2018.PMID:30157247
  3. Lin R-T, Soeberg MJ, Chien L-C, Fisher S, Takala J, Lemen R, Driscoll T, Takahashi K. Bibliometric analysis of gaps in research on asbestos-related diseases: declining emphasis on public health over 26 years. BMJ Open. 2018;8(7):e022806. doi:10.1136/ bmjopen-2018-022806.  PMID:  30049702
  4. Ahmadzada T, Kao S, Reid G, Boyer M, Mahar A, Cooper WA. An update on predictive biomarkers for treatment selection in non-small cell lung cancer. J Clin Med. 2018 Jun 15;7(6).  doi: 10.3390/jcm7060153.  PMID:  29914100
  5. Vafaee F, Diakos C, Kirschner MB, Reid G, Michael MZ, Horvath LG, Alinejad-Rokny H, Cheng ZJ, Kuncic Z, Clarke S. A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. NPJ Syst Biol Appl. 2018 Jun 1;4:20.  doi: 10.1038/s41540-018-0056-1.  PMID:  29872543
  6. Furuya S, Chimed-Ochir O, Takahashi K, David A, Takala J. Global Asbestos Disaster. Int J Environ Res Public Health. 2018 May 16;15(5).  doi: 10.3390/ijerph15051000. PMID:  29772681
  7. Ahmadzada T, Reid G, Kao S. Biomarkers in malignant pleural mesothelioma: current status and future directions. J Thorac Dis. 2018 Apr;10(Suppl 9):S1003-S7.  doi: 10.21037/jtd.2018.04.31.  PMID:  29850181
  8. Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA. FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Carcinogenesis. 2018 Apr 5;39(4):534-45.  doi: 10.1093/carcin/bgy018.  PMID:  29635378
  9. Linton A, Cheng YY, Griggs K, Schedlich L, Kirschner MB, Gattani S, Srikaran S, Kao SC-H, McCaughan BC, Klebe S, van ZandwijkN, Reid G. An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. Br J Cancer. 2018 Mar 20;118(6):e13. doi: 10.1038/bjc.2018.3. Epub 2018 Feb 13. PMID: 29438360
  10. Allen LP, Baez J, Stern MEC, Takahashi K, George F. Trends and the economic effect of asbestos bans and decline in asbestos consumption and production worldwide. Int J Environ Res Public Health. 2018 Mar 16;15(3). doi: 10.3390/ijerph15030531.  PMID: 29547510
  11. Cheng YY, Jin HC, Chan MWY, Chu WK, Grusch M. Epigenetic biomarkers in cancer. Dis Markers. 2018 Feb 20;2018:4987103.  doi: 10.1155/2018/4987103.  PMID: 29675115
  12. van Zandwijk N, McDiarmid J, Brahmbhatt H, Reid G. Response to "An innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)" [Letter]. Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S60-S1. doi: 10.21037/tlcr.2018.01.11.  PMID:  29531907
  13. Johnson TG, Schelch K, Cheng YY, Williams M, Sarun KH, Kirschner MB, Kao S, Linton A, Klebe S, McCaughan BC, Lin RCY, Pirker C, Berger W, Lasham A, van Zandwijk N, Reid G. Dysregulated expression of the microRNA miR-137 and its target YBX1 contribute to the invasive characteristics of malignant pleural mesothelioma. J Thorac Oncol. 2018 Feb;13(2):258-72.  doi: 10.1016/j.jtho.2017.10.016.  PMID:  29113949
  14. Soeberg M, Vallance DA, Keena V, Takahashi K, Leigh J.  Australia's ongoing legacy of asbestos: significant challenges remain even after the complete banning of asbestos almost fifteen years ago. Int J Environ Res Public Health. 2018 Feb;15(2). doi: 10.3390/ijerph15020384.  PMID: 29473898
  15. Ahmadzada T, Reid G, McKenzie DR. Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. Biophys Rev. 2018 Feb;10(1):69-86. doi: 10.1007/s12551-017-0392-1. Epub 2018 Jan 11.  PMID: 29327101
  16. Barnet MB, Zielinski RR, Warby A, Lewis CR, Kao S. Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma. J Thorac Oncol. 2018 Jan; 13(1):e1-e2. doi: 10.1016/j.jtho.2017.09.001. Epub 2017 Sep 12. PMID: 28919393
  17. Schelch K, Kirschner MB, Williams M, Cheng YY, van Zandwijk N, Grusch M, Reid G. A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma. Mol Oncol. 2018 Jan; 12(1):58-73. doi: 10.1002/1878-0261.12150. Epub 2017 Nov 18. PMID: 29094504
  18. GBD 2017 Mortality Collaborators (incl. Takahashi K). Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018, 392 (10159): 1684-1735. doi:https://doi.org/10.1016/S0140-6736(18)31891-9
  19. GBD 2017 Causes of Death Collaborators ( Takahashi K). Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018, 392 (10159): 1736-1788. doi:https://doi.org/10.1016/S0140-6736(18)32203-7
  20. GBD 2017 Risk Factor Collaborators ( Takahashi K). Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018, 392 (10159): 1923-1994. doi:https://doi.org/10.1016/S0140-6736(18)32225-6
  21. Talaulikar D, Biscoe A, Lim JH, Gibson J, Arthur C, Mackinlay N, Saxena K, Cheng YY, Chen VM. Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenström Macroglobulinaemia reveals different patterns of clonal evolution. Br J Haematol. 2018. Oct 18. doi: 10.1111/bjh.15610. [Epub ahead of print]. PMID: 30338525
  22. Sarun KH, Lee K, Williams M, Wright CM, Clarke CJ, Cheng NC, Takahashi K, Cheng YY. Genomic deletion of BAP1 and CDKN2A are useful markers for quality control of malignant pleural mesothelioma (MPM) primary cultures. J. Mol. Sci. 2018, 19(10), 3056; https://doi.org/10.3390/ijms19103056. PMID: 30301262
  23. Li W, Hu X, Yang S, Wang S, Zhang C, Wang H, Cheng YY, Wang Y, Liu T, Song K. A novel tissue-engineered 3D tumor model for anti-cancer drug discovery. Biofabrication. 2018;11(1):015004. doi: 10.1088/1758-5090/aae270. PMID: 30229749
  24. Rath EM, Cheng YY, Pinese M, Sarun KH, Hudson AL, Weir C, Wang YD, Håkansson AP, Howell VM, Liu GJ, Reid G, Knott RB, Duff AP, Church WB. BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. PloS One. 2018 Aug 29;13(8):e doi: 10.1371/journal.pone.0203003. eCollection 2018. PMID: 30157247
  25. Lin R-T, Soeberg MJ, Chien L-C, Fisher S, Takala J, Lemen R, Driscoll T, Takahashi K. Bibliometric analysis of gaps in research on asbestos-related diseases: declining emphasis on public health over 26 years. BMJ Open. 2018;8(7):e022806. doi:10.1136/ bmjopen-2018-022806. PMID: 30049702
  26. Ahmadzada T, Kao S, Reid G, Boyer M, Mahar A, Cooper WA. An update on predictive biomarkers for treatment selection in non-small cell lung cancer. J Clin Med. 2018 Jun 15;7(6). doi: 10.3390/jcm7060153.  PMID: 29914100
  27. Vafaee F, Diakos C, Kirschner MB, Reid G, Michael MZ, Horvath LG, Alinejad-Rokny H, Cheng ZJ, Kuncic Z, Clarke S. A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. NPJ Syst Biol Appl. 2018 Jun 1;4:20. doi: 10.1038/s41540-018-0056-1.  PMID: 29872543
  28. Furuya S, Chimed-Ochir O, Takahashi K, David A, Takala J. Global Asbestos Disaster. Int J Environ Res Public Health. 2018 May 16;15(5). doi: 10.3390/ijerph15051000. PMID: 29772681
  29. Ahmadzada T, Reid G, Kao S. Biomarkers in malignant pleural mesothelioma: current status and future directions. J Thorac Dis. 2018 Apr;10(Suppl 9):S1003-S7. doi: 10.21037/jtd.2018.04.31.  PMID: 29850181
  30. Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA. FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Carcinogenesis. 2018 Apr 5;39(4):534-45. doi: 10.1093/carcin/bgy018.  PMID: 29635378
  31. Linton A, Cheng YY, Griggs K, Schedlich L, Kirschner MB, Gattani S, Srikaran S, Kao SC-H, McCaughan BC, Klebe S, van ZandwijkN, Reid G. An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. Br J Cancer. 2018 Mar 20;118(6):e13. doi: 10.1038/bjc.2018.3. Epub 2018 Feb 13. PMID: 29438360
  32. Allen LP, Baez J, Stern MEC, Takahashi K, George F. Trends and the economic effect of asbestos bans and decline in asbestos consumption and production worldwide. Int J Environ Res Public Health. 2018 Mar 16;15(3). doi: 10.3390/ijerph15030531. PMID: 29547510
  33. Cheng YY, Jin HC, Chan MWY, Chu WK, Grusch M. Epigenetic biomarkers in cancer. Dis Markers. 2018 Feb 20;2018:4987103. doi: 10.1155/2018/4987103.  PMID: 29675115
  34. van Zandwijk N, McDiarmid J, Brahmbhatt H, Reid G. Response to "An innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)" [Letter]. Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S60-S1. doi: 10.21037/tlcr.2018.01.11.  PMID: 29531907
  35. Johnson TG, Schelch K, Cheng YY, Williams M, Sarun KH, Kirschner MB, Kao S, Linton A, Klebe S, McCaughan BC, Lin RCY, Pirker C, Berger W, Lasham A, van Zandwijk N, Reid G. Dysregulated expression of the microRNA miR-137 and its target YBX1 contribute to the invasive characteristics of malignant pleural mesothelioma. J Thorac Oncol. 2018 Feb;13(2):258-72. doi: 10.1016/j.jtho.2017.10.016.  PMID: 29113949
  36. Soeberg M, Vallance DA, Keena V, Takahashi K, Leigh J. Australia's ongoing legacy of asbestos: significant challenges remain even after the complete banning of asbestos almost fifteen years ago. Int J Environ Res Public Health. 2018 Feb;15(2). doi: 10.3390/ijerph15020384.  PMID: 29473898
  37. Ahmadzada T, Reid G, McKenzie DR. Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. Biophys Rev. 2018 Feb;10(1):69-86. doi: 10.1007/s12551-017-0392-1. Epub 2018 Jan 11. PMID: 29327101
  38. Barnet MB, Zielinski RR, Warby A, Lewis CR, Kao S. Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma. J Thorac Oncol. 2018 Jan; 13(1):e1-e2. doi: 10.1016/j.jtho.2017.09.001. Epub 2017 Sep 12. PMID: 28919393
  39. Schelch K, Kirschner MB, Williams M, Cheng YY, van Zandwijk N, Grusch M, Reid G. A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma. Mol Oncol. 2018 Jan; 12(1):58-73. doi: 10.1002/1878-0261.12150. Epub 2017 Nov 18. PMID: 29094504

2017

  1. Cheng YY, Mok E, Tan S, Leygo C, George AM, Reid G. SFRP tumour suppressor genes are potential plasma-based epigenetic biomarkers for malignant pleural mesothelioma. Disease Markers: July 2017: 2536187. PMID: 29386699
  2. Leygo C, Williams M, Jin HC, Chan MWY, Chu WK, Grusch M, Cheng YY. DNA methylation as a noninvasive epigenetic biomarker for the detection of cancer. Dis Markers. 2017:3726595.  PMID: 29038612
  3. Furuya S, Takahashi K. Experience of Japan in achieving a total ban on asbestos. Int J Environ Res Public Health. 2017;14(10):1261. PMID: 29053631
  4. GBD_2016_Causes_of_Death_Collaborators, (Takahashi K, included). Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151-210. PMID: 28919116
  5. Global_Burden_of_Disease_Cancer_Collaboration, (Takahashi K, included). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524-48. PMID: 27918777
  6. Kresoja-Rakic J, Sulemani M, Kirschner MB, Ronner M, Reid G, Kao S, Schwaller B, Weder W, Stahel RA, Felley-Bosco E. Posttranscriptional regulation controls calretinin expression in malignant pleural mesothelioma. Front Genet. 2017 May 29;8:70. doi: 10.3389/fgene.2017.00070. eCollection 2017. PMID: 28611824
  7. van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017; http://dx.doi.org/10.1016/S1470-2045(17)30596-X PMID: 28870611
  8. Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G. Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. J Thorac Oncol. 2017;12(9):1421-33. PMID: 28629895
  9. Sawanyawisuth K, Furuya S, Park EK, Myong JP, Ramos-Bonilla JP, Chimed Ochir O, Takahashi K. Compensation for asbestos-related diseases in Japan: utilization of standard classifications of industry and occupations. Asian Pac J Cancer Prev. 2017;18(7):1779-82. PMID: 28749105
  10. Odgerel C-O, Takahashi K, Sorahan T, Driscoll T, Fitzmaurice C, Yoko-o M, Sawanyawisuth K, Furuya S, Tanaka F, Horie S, van Zandwijk N, Takala J. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup Environ Med. 2017; [Epub ahead of print]. PMID: 28866609
  11. Takala J, Hamalainen P, Nenonen N, Takahashi K, Chimed-Ochir O, Rantanen J. Comparative analysis of the burden of injury and illness at work in selected countries and regions. Cent Eur J Occup Environ Med. 2017;23(1-2):6-31.
  12. Robb T, Reid G, Blenkiron C. Exploiting microRNAs as cancer therapeutics. Target Oncol. 2017;12(2):163-78. PMID: 28138797
  13. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crino L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Perol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol. 2017;12(2):194-207. PMID: 27729297
  14. Linton A, Soeberg M, Broome R, Kao S, van Zandwijk N. Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes. Respirology. 2017;22(5):978-85. PMID: 28139858

2016

  1. Williams M, Cheng YY, Blenkiron C, Reid G. Exploring mechanisms of microRNA downregulation in cancer. MicroRNA. 2016 Dec 8. [Epub ahead of print] PMID: 27928946
  2. Soeberg MJ, Leigh J, van Zandwijk N. Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends. J Toxicol Environ Health B Crit Rev. 2016;19(5-6):173-89. PMID: 27705544
  3. Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, Stockhammer P, Ozsvar J, Jakopovic M, Samarzija M, Brcic L, Bendek M, Szirtes I, Reid G, Kirschner MB, Kao SC, Opitz I, Weder W, Frauenfelder T, Nguyen-Kim TD, Aigner C, Klepetko W, van Zandwijk N, Berger W, Dome B, Grusch M, Hegedus B. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. Eur J Cancer. 2016 Aug;63:64-73. PMID: 27288871
  4. Driml J, Pulford E, Moffat D, Karapetis C, Kao S, Griggs K, Henderson DW, Klebe S. Usefulness of Aquaporin 1 as a prognostic marker in a prospective cohort of malignant mesotheliomas. Int J Mol Sci. 2016 Jun;17(7), 1041. PMID: 27376267
  5. Bremnes RM, Busund LT, Kilvaer TL, Andersen S, Richardsen E, Paulsen EE, Hald S, Khanehkenari MR, Cooper WA, Kao SC, Donnem T. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol. 2016 Jun;11(6):789-800. PMID: 26845192
  6. Soeberg MJ, Creighton N, Currow DC, Young JM, van Zandwijk N. Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, Australia, 1972-2009. Aust N Z J Public Health. 2016 Jun;40(3):255-62. PMID: 26713662
  7. Cheng YY, Wright CM, Kirschner MB, Williams M, Sarun KH, Sytnyk V, Leshchynska I, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, van Zandwijk N, Lin RCY, Reid G.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. Mol Cancer. 2016 Jun 1;15(1):44. PMID: 27245839
  8. Lin RCY, Kirschner MB, Cheng YY, van Zandwijk N, Reid G. MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. Genom Data. 2016 9:44-9. Doi:10.1016/j.gdata.2016.06.009
  9. Reid G, Kao SC, Pavlakis N, Brahmbhatt H, MacDiarmid J, Clarke S, Boyer M, van Zandwijk N. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics. 2016;8(8):1079-85. PMID: 27185582
  10. Soeberg MJ, Luong MA, Tran VT, Tran AT, Nguyen TTH, Bui D, Nguyen THN, Takahashi K, van Zandwijk N. Estimating the incidence of malignant mesothelioma in Vietnam: a pilot descriptive cancer registration study. Int J Occup Environ Health. 2016 Apr;22(2):167-72. PMID: 27388204
  11. Kao SC, Boyer MJ. Evolving landscape of epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2016;34(27):3233-4. PMID: 27069076
  12. Kao SC, Kirschner MB, Cooper WA, Tran T, Burgers S, Wright C, Korse T, van den Broek D, Edelman J, Vallely M, McCaughan B, Pavlakis N, Clarke S, Molloy MP, van Zandwijk N, Reid G. A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. Br J Cancer. 2016 Mar 1;114(5):524-31. PMID: 26889976
  13. van Zandwijk N, Soeberg M, Reid G. Using a multidisciplinary approach to combat the burden of asbestos-related disease. Med J Aust. 2016 Feb 1;204(2) : 52. PMID: 26821095
  14. Soeberg M J, Leigh J, Driscoll T, Armstrong B, Young JM, van Zandwijk N. Incidence and survival trends in malignant pleural and peritoneal mesothelioma, Australia, 1982-2009. Occup Environ Med. 2016 Mar;73(3):187-94.  PMID: 26800709

2015

  1. Soeberg M, van Zandwijk N. Incidence of malignant mesothelioma in New Zealand and Australia – a global snapshot. [Letter] NZ Med J. 2015;128(1427):68-71. PMID: 26914008
  2. Glover AR, Zhao JT, Gill AJ, Weiss J, Mugridge N, Kim E, Feeney AL, Ip JC, Reid G, Clarke S, Soon PS, Robinson BG, Brahmbhatt H, MacDiarmid JA, Sidhu SB. microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. 2015 Nov 3;6(34):36675-88. PMID: 26452132
  3. Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, Edelman JJB, Kao SC, Hyland R, Dong Y, László V, Klikovits T, Vallely MP, Grusch M, Hegedus B, Dome B, Klepetko W, van Zandwijk N, Klebe S, Reid G. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer. 2015 Sep 15; 113(6): 963-9. PMID: 26263483
  4. Williams M, Kirschner MB, Cheng YY, Hanh J, Weiss J, Mugridge N, Wright CM, Linton A, Kao SC, Edelman JJB, Vallely MP, McCaughan BC, Cooper W, Klebe S, Lin RCY, Brahmbhatt H, MacDiarmid J, van Zandwijk N, Reid G. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget. 2015 Sep 15; 6(27):23480-95. PMID: 26125439
  5. Kao SC, Fulham M, Wong K, Cooper W, Brahmbhatt H, MacDiarmid J, Pattison S, Sagong JO, Huynh Y, Leslie F, Pavlakis N, Clarke S, Boyer M, Reid G,  van Zandwijk N. A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. [To the Editor] Am J Respir Crit Care Med. 2015;191(12):1467-1469.  PMID: 26075427
  6. Reid G. MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets. J Thorac Dis. 2015 Jun;7(6):1031-40. PMID: 26150916
  7. Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. 2015 Aug;89(2):181-8. PMID: 26024796
  8. Birnie KA, Yip YY, Ng DCH, Kirschner MB, Reid G, Prele CM, Musk AW, Lee YCG, Thompson PJ, Mutsaers SE, Badrian B. Loss of mir-223 and JNK signalling contribute to elevated Stathmin in malignant pleural mesothelioma. Mol Cancer Res. 2015 Jul;13(7):1106-18. PMID: 25824152
  9. Klebe S, Griggs K, Cheng Y, Driml J, Henderson DW, Reid G. Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo Dis Markers. 2015;2015:286719. PMID: 25821338
  10. Luk PP, Yu B, Ng CC, Mercorella B, Selinger C, Lum T, Kao S, O'Toole SA, Cooper WA. BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res. 2015 Apr;4(2):142-8. PMID: 25870796
  11. Kumarakulasinghe NB,van Zanwijk N, Soo RA. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Fong KM, van Zanwijk N. (Series Ed.) Invited Review Series: Lung cancer practice, implementing evidence around the world.   2015 Apr;20(3):370-8.  PMID: 25689095
  12. van Zandwijk N, Fong KM. Update in lung cancer: Prologue to a modern review series. Fong KM, van Zandwijk N. (Series Ed.) Series Editorial – Prologue: Lung cancer practice, implementing evidence around the world. Respirology. 2015 Feb;20(2):183–4. PMID: 25594901
  13. Kao SC-H, van Zandwijk N, Clarke S, Vardy J, Lumba S, Tognela A, Ng W. Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence-based benchmark for cancer care. Asia Pac J Clin Oncol. 2015 Mar;11(1): 85-92. PMID: 25382807
  14. Kirschner MB, Cheng YY, Armstrong NJ, Lin RCY, Kao SC, Linton A, Klebe S, McCaughan BC, van Zandwijk N, Reid G. MiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Mol Oncol. 2015 Mar;9(3):715-26.  PMID: 25497279
  15. Lin RCY, van Zandwijk N, Reid G. MicroRNA therapeutics – back in vogue? Editorial. J Investig Genomics. 2015;2(1):00012.

2014

  1. Soeberg M, van Zandwijk N. The ticking time-bomb of asbestos consumption in the Asian region. Asia-Pac Newsl Occup Health Safety. 2014 Nov;21(2):24-7.
  2. Lin RCY, Ng S-F, Morris MJ. Gene expression in rat models for inter-generational transmission of islet dysfunction and obesity. Data in brief. Genom Data. 2014 Dec;2:351-3. PMID: 26484128
  3. Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer. 2014 Oct 28;111(9):1860-9. PMID: 25188323
  4. Kao SC-H, van Zandwijk N, Clarke S. Comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant pleural mesothelioma’. Br J Cancer. 2014 Dec 9;111(12):2376. PMID: 24714747
  5. Cheng NC, van Zandwijk N, Reid G. Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ PLoS One. 2014 Mar 3;9(3):e90374.  PMID: 24595274
  6. Linton A, Cheng YY, Griggs K, Kirschner MB, Gattani S, Srikaran S, Kao SC-H, McCaughan BC, Klebe S, van Zandwijk N, Reid G. An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. Br J Cancer. 2014 Jan 21;110(2):510-9.  PMID: 24327015

2013

  1. Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, Williams M, Wright C, Edelman JJB, Vallely MP, McCaughan BC, Klebe S, Brahmbhatt H, MacDiarmid JA, van Zandwijk N. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013 Dec;24(12):3128–35. PMID: 24148817
  2. van Zandwijk N. Clinical practice guidelines for malignant pleural mesothelioma. J Thorac Dis. 2013 Dec;5(6):724-5. PMID: 24409346
  3. van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, Loneragan R, McCaughan B, Boyer M, Feigen M, Currow D, Schofield P, Ivimey B, Pavlakis N, McLean J, Marshall H, Leong S, Keena V, Penman A. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013 Dec;5(6):E254-307. (Review) PMID: 24416529
  4. Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, de Rink I, Greger L, Hooijer GKJ, Peters D, Nederlof PM, Hofland I, de Jong J, Wesseling J, Kluin RJC, Brugman W, Kerkhoven R, Nieboer F, Roepman P, Broeks A, Muley TR, Jassem J, Niklinski J, van Zandwijk N, Brazma A, Oshlack A, van den Heuvel M, Bernards R. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol. 2013 Jul;230(3):270-6. PMID: 23661334
  5. Wright CM, Kirschner MB, van Zandwijk N, Reid G. Does miR-1 play a role in malignant pleural mesothelioma development and progression? Chest 2013 Dec;144 (6):1971. PMID: 24297134
  6. Cheng YY, Kirschner MB, Cheng NC, Gattani S, Klebe S, Edelman JJB, Vallely MP, McCaughan BC, Jin HC, van Zandwijk N, Reid G. ZIC1 is silenced and has tumour suppressor function in malignant pleural mesothelioma. J Thorac Oncol. 2013 Oct; 8(10):1317-28.  PMID: 24457242
  7. Honeyball F, Boyer M, van Zandwijk N, Kao SC. Malignant pleural mesothelioma. CancerForum. 2013;37(2). Available from: http://cancerforum.org.au/forum/2013/july/malignant-pleural-mesothelioma/
  8. Wright CM, Kirschner MB, Cheng YY, O’Byrne KJ, Gray SG, Schelch K, Hoda MA, Klebe S, McCaughan B, van Zandwijk N, Reid G. Long non coding RNAs (lncRNAs) are dysregulated in malignant pleural mesothelioma (MPM). PLoS One. 2013 Aug 19;8(8):e70940. PMID: 23976967
  9. Lim CB, Prêle CM, Cheah HM, Cheng YY, Klebe S, Reid G, Watkins DN, Baltic S, Thompson PJ, Mutsaers SE. Mutational analysis of Hedgehog signaling pathway genes in human malignant mesothelioma. PLoS One. 2013 Jun 24;8(6):e66685. PMID: 23826113
  10. Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013 Oct;66(10):847-53. PMID: 23814259
  11. Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2: Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1and microRNA. J Clin Pathol. 2013 Oct;66(10):854-61. PMID: 23833051
  12. Kirschner MB, Edelman JJB, Kao SC-H, Vallely MP, Van Zandwijk N, Reid G. The impact of hemolysis on cell-free microRNA biomarkers. Front Genet. 2013 May 24; 4:94. PMID: 23745127
  13. Kirschner MB, van Zandwijk N, Reid G. Cell-free microRNAs: potential biomarkers in need of standardized reporting. Front Genet. 2013 April 19; 4:56.  PMID: 23626598
  14. Kao SC, van Zandwijk N, Corte P, Clarke C, Clarke S, Vardy J. Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. Support Care Cancer. 2013 Jul; 21(7):1879-1884. PMID: 23408016
  15. Cheng ASL, Li MS, Kang W, Cheng VY, Chou J-L, Lau SS, Go MY, Lee CC, Ling TK, Ng EK, Yu J, Huang TH, To KF, Chan MW, Sung JJY, Chan FKL. Helicobacter pylori Causes epigenetic dysregulation of foxd3 to promote gastric carcinogenesis. 2013 Jan; 144(1):122-133.e9. PMID: 23058321
  16. Kao SC, Vardy J, Harvie R, Chatfield M, van Zandwijk N, Clarke S, Pavlakis N. Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Support Care Cancer. 2013 Mar;21(3):697-705. PMID: 22936495
  17. Kao SC, Vardy J, Chatfield M, Corte P, Pavlakis N, Clarke C, van Zandwijk N, Clarke S. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer. 2013 Jan;14(1):70-7. PMID: 22658812 (Highly Cited Research in Clinical Lung Cancer awarded December 2016)
  18. Kao SCH, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, Clarke S, van Zandwijk N. Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma. Clin Lung Cancer. 2013 Mar;14(2):164-71. PMID: 23085037
  19. Linton A, Kao S, Vardy J, Clarke S, van Zandwijk N, Klebe S. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review. Asia Pac J Clin Oncol. 2013 Sep;9(3):273-79. PMID: 23167246
  20. Kao SC-H, Clarke S, Vardy J, Corte P, Clarke C, van Zandwijk N. Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. Intern Med J. 2013 Apr;43(4):402-10.  PMID: 22909129

2012

  1. Linton A, van Zandwijk, Reid G, Clarke S, Cao C, Kao S. Inflammation in malignant mesothelioma – friend or foe? Ann Cardiothorac Surg. 2012 Nov;1(4):516-22. PMID: 23977546
  2. van Zandwijk N, Reid G, Linton A, Kao S. Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools? Ann Cardiothorac Surg. 2012 Nov;1(4):481-86.  PMID: 23977540
  3. Kao SC-H, Armstrong N, Condon B, Griggs K, McCaughan B, Maltby S, Wilson A, Henderson DW, Klebe S. Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma. Cancer. 2012 Jun 1;118(11):2952-61. PMID: 22020536
  4. Linton A, Vardy J, Clarke S, van Zandwijk N. The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma. Crit Rev Oncol Hematol. 2012 Nov;84(2):200-12. PMID: 22459593
  5. Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJB, Armstrong NJ, Vallely MP, Musk AW, Robinson BWS, McCaughan BC, Klebe S, Mutsaers SE, van Zandwijk N, Reid G. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012 Jul;7(7):1184-91. PMID: 22617246
  6. Manegold C, van Zandwijk N, Szczesna A,  Zatloukal P, Au JSK, Blasinska-Morawiec M, Serwatowski P, Krzakowski M,  Jassem J,  Tan EH, Benner RJ, Ingrosso A, Meech SJ,  Readett D, Thatcher N. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung Ann Oncol. 2012 Jan;23(1):72–7.  PMID: 21464154
  7. Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW. YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst. 2012 Jan 18;104(2):133–46.  PMID: 22205655

2011

  1. Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, Nakano T, Pass HI, Robinson BWS, Rusch VW, Sugarbaker DJ, van Zandwijk N. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol. 2011 Nov;12(12):1093-4. PMID: 22041539
  2. Kao SC-H, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, Yan TD, Vardy J, Clarke S, van Zandwijk N, McCaughan B. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol. 2011 Nov;6(11):1923-9. PMID: 22011651
  3. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2011 Nov;80(2):193–208. PMID: 21145252
  4. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One. 2011;6(9):e24145. PMID: 21909417
  5. Kao SC-H, Griggs K, Lee K, Armstrong N, Clarke S, Vardy J, van Zandwijk N, Burn J, McCaughan BC, Henderson DW, Klebe S. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology. 2011 Jun;43(4):313-7. PMID: 21532523
  6. Herbert M, Coppieters N , Lasham  A, Cao H, Reid G. The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing. BMC Res Notes. 2011 May 25;4:148.  PMID: 21612654
  7. Heigener DF, Wu YL, van Zandwijk N, Mali P, Horwood K, Reck M. Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study. Lung Cancer. 2011 Nov;74(2):274-9. PMID: 21439671
  8. Kao SC-H, Lee K, Armstrong NJ, Clarke S, Vardy J, van Zandwijk N, Reid G, Burn J, McCaughan BC, Henderson DW, Klebe S. Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology. 2011 Feb;43(2):128-32. PMID: 21233673
  9. Kao SC-H, Reid G, van Zandwijk N, Henderson DW, Klebe S. Molecular biomarkers in malignant mesothelioma - state of the art. Pathology. 2011 Apr;43(3):201-12. PMID: 21436629
  10. Kao SC-H, Yan TD, Lee K, Burn J, Henderson DW, Klebe S, Kennedy C, Vardy J, Clarke S, van Zandwijk N, McCaughan BC. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J Thorac Oncol. 2011 Mar;6(3):602-5. PMID: 21266919
  11. Li Y, Revalde L, Reid G, Paxton JW. Modulatory effects of curcumin on multi-drug resistance associated protein 5 in pancreatic cancer cells. Cancer Chemother Pharmacol. 2011 Sep;68(3):603-10.  PMID: 21116627
  12. Kao SCH, Butow P, Bray V, Clarke SJ, Vardy J. Patient and oncologist estimates of survival in advanced cancer patients. Psychooncology. 2011 Feb;20(2):213-8.  PMID: 20878829

2010

  1. Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M, Heigener D. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol. 2010 Oct;5(10):1616-22. PMID: 20736854
  2. Li Y, Revalde JL, Reid G, Paxton JW. Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. Drug Metab Rev. 2010 Nov;42(4):590-611. PMID: 20433315
  3. Lasham A, Herbert M, Coppieters 't Wallant N, Patel R, Feng S, Eszes M, Cao H, Reid G. A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probe. Nucleic Acids Res. 2010 Jan;38(3):e19. PMID: 19942683
  4. Kappers I, van Sandick JW, Burgers SA, Belderbos JSA, van Zandwijk N, Klomp HM. Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided. Lung Cancer. 2010 May;68(2):222-7. PMID: 19664843
  5. Kao SC-H, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N. Malignant Mesothelioma. Intern Med J. [Review]. 2010 Nov;40(11):742–50. PMID: 20298508
  6. Kao SC-H, Phan VH, Clarke SJ. Predictive markers for haematological toxicity of pemetrexed. Curr Drug Targets. 2010 Jan;11(1):48-57. PMID: 19839928
  7. Kao SC-H, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010 Dec 1; 16(23):5805-13. PMID: 20956618
  8. Kao SC-H, McCaughan B, Muljono A, Boyer M. A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed. J Thorac Oncol. 2010 Mar;5(3):405-6. PMID: 20186029
  9. Cheng YY, Chau D, Chan T, Gill H, Liang R, Kwong YL, Tse E. Absence of NPM1 promoter hypermethylation in human myelodysplastic syndrome. J Clin Pathol. 2010 Nov; 63(11):1008-11. PMID: 20924036
  10. Smit EF, Groen HJM, van Zandwijk N. Reply to L. H. de Lima Araújo et al. J Clin Oncol. 2010 Jan 10;28(2):e26.
  11. Kappers I, Vollebergh MA, van Tinteren H, Korse CM, Nieuwenhuis LL, Bonfrer JMG, Klomp HM, van Zandwijk N, van den Heuvel MM. Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment. Ecancermedicalscience. 2010;4:178.  PMID: 22276032

2009

  1. van Zandwijk N. Individualization of treatment in non-small cell lung cancer. F1000 Med Rep. 2009 Mar 24;1:24. PMID: 20948757
  2. Van den Heuvel MM, Burgers SA, van Zandwijk N. Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination. Clin Lung Cancer. 2009 Mar;10(2):99-105. PMID: 19362952
  3. Smit EF, Burgers SA, Biesma B, Smit HJM, Eppinga P, Dingemans A-MC, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJM. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009 Apr 20;27(12):2038-45. PMID: 19307503
  4. Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, Witteveen AT, Rzyman W, Floore A, Burgers S, Giaccone G, Meister M, Dienemann H, Skrzypski M, Kozlowski M, Mooi WJ, van Zandwijk N. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res. 2009 Jan 1;15(1):284-90. PMID: 19118056
  5. Reid G, Coppieters 't Wallant N, Patel R, Antonic A, Saxon-Aliifaalogo F, Cao H, Webster G, James D Watson JD. Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. J RNAi Gene Silencing. 2009 Mar 9;5(1):321-30.  PMID:19771229
  6. Patel R, Coppieters 't Wallant N, Herbert MH, White D, Murison JG, Reid G. The potency of siRNA-mediated growth inhibition following silencing of essential genes is dependent on siRNA design and varies with target sequence. Oligonucleotides. 2009 Dec;19(4):317-28. PMID: 19943803
  7. Kappers I, van Sandick JW, Burgers JA, Belderbos JSA, Wouters MW, van Zandwijk N, Klomp HM. Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. Eur J Cardiothorac Surg. 2009 Oct;36(4):741-6. PMID: 19699647
  8. Kao S, Mahon K, Lin B, Rutland J, Pawsey C, McCaughan B, Beale P. Pleural well-differentiated papillary mesothelioma: a case report. J Thorac Oncol. 2009 Jul;4(7):920-2. PMID: 19550246
  9. Geurts TW, van Velthuysen MLF, Broekman F, van Huysduynen TH, van den Brekel MWM, van Zandwijk N, van Tinteren H, Nederlof P, Balm AJM, Brakenhoff RH. Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis. Clin Cancer Res. 2009 Feb 1;15(3):980-5. PMID: 19188169
  10. Geurts TW, Balm AJM, van Velthuysen M-LF, van Tinteren H, Burgers JA, van Zandwijk N, Klomp HM. Survival after surgical resection of pulmonary metastases and second primary squamous cell lung carcinomas in head and neck cancer. Head Neck. 2009 Feb;31(2):220-6.  PMID: 18972427

Book Chapters

2017

  1. Gulati S, Mulshine JL, van Zandwijk N. Section 1: Lung Cancer Control and Epidemiology, 9 - Chemoprevention of Lung Cancer and Management of Early Lung Cancer. In: Pass HI, Ball D, Scagliotti GV, editors. IASLC Thoracic Oncology (Second Edition): Elsevier Inc.; 2017. p. 69-81.e5.  ISBN 978-0-323-52357-8

2016

  1. Soeberg M, van Zandwijk N. Chapter 9: Asbestos and malignant pleural mesothelioma. In: Mineo TC (ed) Malignant pleural mesothelioma: Present status and future direction. Benthem Science Publishers; 2016 (eBook). Chapter 9; p115-128. eISBN 978-1-68108-193-9. ISBN 978-1-68108-194-6 http://ebooks.benthamscience.com/book/9781681081939/

2015

  1. Maher SG, Bibby BAS, Moody HL, Reid G. MicroRNAs and Cancer. In: Gray SG, Editor, Epigenetic Cancer Therapy, Translational Epigenetics Series. Elsevier; 2015. Chapter 4; p67-90.  ISBN 978-0-12-800206-3
  2. Wright CM. Long noncoding RNAs and cancer. In: Gray SG, Editor, Epigenetic Cancer Therapy, Translational Epigenetics Series. Elsevier; 2015. Chapter 5; p91-114. ISBN 978-0-12-800206-3

2014

  1. Gulati S, Mulshine JL, van Zandwijk N. Chapter 9: Chemoprevention of lung cancer and management of early lung cancer. In: Pass HI (ex. editor), Ball D, Scagliotti GV (eds.) The IASLC Multidisciplinary Approach to Thoracic Oncology.  Aurora, CO: International Association for the Study of Lung Cancer. 2014: 105-123

2010

  1. van Zandwijk N. Occurrence and chemoprevention of lung cancer. In: Manegold C, editor. Non-small cell lung cancer treatment. Beijing: People's Medical Publishing House; 2010. p. 117-33.
  2. van Zandwijk N. Lung Carcinogenesis and Chemoprevention. In Manegold C. Non-Small Cell Lung cancer Treatment. 2nd Ed. Uni-Med Verlag AG. Bremen 2010; 15:165-176
  3. Khuri F, van Zandwijk N. Chapter 21: Molecular carcinogenesis and chemoprevention of lung cancer. In: Pass HI, Carbone DP, Johnson DH, Minna JD, Scagliotti GV, Turrisi III AT (eds.) Principals and Practice of Lung Cancer: The official reference text of the IASLC. 4th Ed. Lippincott, Williams & Wilkens, Philadelphia, USA. 2010: 275-283

2009

  1. van Zandwijk N. Lung cancer: oncogenesis and prevention. In: Thoracic Malignancies. Spiro SG, Huber RM, Janes SM, editors. The European Respiratory Monograph, Plymouth, UK: European Respiratory Society Journals; 2009: 1-14

Guidelines

2013

  1. Guidelines for the Diagnosis and Treatment of Malignant Pleural Mesothelioma

Asbestos Diseases Research Institute, July 2013

For more information on the Guidelines for the Diagnosis and Treatment of Malignant Pleural Mesothelioma, click here.